Compare Ascendis Pharma A/S (ASND) vs F5 Inc (FFIV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs F5 Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while F5 Inc trades at $429.86 (market cap $24.28B). The key difference: F5 Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| ASND | FFIV | |
|---|---|---|
Market Cap | $17.74B | $24.28B |
Sector | Health | Technology |
52-Week High | $277.18 | $430.39 |
52-Week Low | $163.32 | $223.99 |
Enterprise Value | $18.11B | $23.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
F5 (FFIV) trades at $430.39, showing minimal daily movement with a 0.02% gain. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $3.09B in 2025. Technical indicators signal a bullish trend, with the price above key support levels. Recent strategic moves include AI security platform expansion and acquisitions, positioning the company for continued growth in the cybersecurity sector.
The outlook remains positive with strong earnings momentum and strategic AI investments, though valuation metrics appear elevated. Key risks include competitive pressures and execution challenges in new market segments. Analyst consensus leans cautious with a $397 price target below current levels, suggesting potential near-term consolidation despite long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →
